InMed reports Q2 net loss $2.6M, cash $3.5M; board accepts director resignation

InMed Pharmaceuticals Inc.

2025-Q2 EPS reported -$6.43 revenue$2,376,345

Net loss of $2.6M for Q2 FY2025 (Dec 31, 2024), vs $1.5M loss a year ago; GAAP loss per share $3.64.
Cash and equivalents $3.5M as of Dec 31, 2024; company raised $2.9M in Jan 2025, enough through Q2 2025.
BayMedica revenue $1.1M (-10% YoY); BayMedica achieved net income of $0.23M (189% improvement).
Board accepted resignation of director Janet Grove effective Feb 10, 2025, following withheld votes at Dec 2024 AGM.
R&D expenses $1M (up from $0.6M); pipeline updates: INM-901 (Alzheimer's) and INM-089 (dry AMD).

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Janet Grove

Director

INM · InMed Pharmaceuticals Inc.

Effective: 2025-02-10
Filed: February 14, 2025, 6:59 PM ET

On February 10, 2025, the Board elected to accept Ms. Grove’s resignation from the Board, including from her positions as a member of the Compensation Committee and Chair of the Nominating & Governance Committee.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Janet Grove resigned as Director at InMed Pharmaceuticals Inc..

Action: resigned
Role: Director

Exact text from the filing

On February 10, 2025, the Board elected to accept Ms. Grove’s resignation from the Board, including from her positions as a member of the Compensation Committee and Chair of the Nominating & Governance Committee.

View on SEC.gov

InMed Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-014154

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.